Jim Birchenough
Stock Analyst at Wells Fargo
(2.35)
# 2,091
Out of 4,667 analysts
40
Total ratings
38.1%
Success rate
13.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Maintains: Equal-Weight | $2 → $3 | $1.40 | +114.29% | 5 | Mar 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $46.29 | +51.22% | 3 | Feb 22, 2024 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $1 | $1.96 | -48.98% | 1 | Nov 6, 2023 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $2.81 | +1,323.49% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $13.68 | +250.88% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.64 | +999.59% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $2.07 | +6,180.19% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $0.90 | +1,450.56% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $38.25 | +279.08% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $89.76 | -29.81% | 5 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $42.56 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $5.85 | +858.08% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $744.50 | -1.41% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $7.62 | +2,262.20% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $6.33 | +421.33% | 3 | Jun 28, 2018 |
Regulus Therapeutics
Mar 13, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $1.40
Upside: +114.29%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $46.29
Upside: +51.22%
Sangamo Therapeutics
Nov 6, 2023
Downgrades: Equal-Weight
Price Target: $1
Current: $1.96
Upside: -48.98%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $2.81
Upside: +1,323.49%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $13.68
Upside: +250.88%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.64
Upside: +999.59%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $2.07
Upside: +6,180.19%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $0.90
Upside: +1,450.56%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $38.25
Upside: +279.08%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $89.76
Upside: -29.81%
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $42.56
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $5.85
Upside: +858.08%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $744.50
Upside: -1.41%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $7.62
Upside: +2,262.20%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $6.33
Upside: +421.33%